Clinical Trials

36 enrolled

Prostatic Neoplasms

NCT07182279 2026-03-09

Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer

29 enrolled

Adenocarcinoma, Prostatic Neoplasms

NCT06066437 2026-03-05

NeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial

6 enrolled

Prostatic Neoplasms

NCT06237179 2026-03-02

EXTRA-PC

Motor Activity, Prostatic Neoplasms

NCT06434350 2026-03-02

Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE)

41 enrolled

Phase 1/2 Not yet recruiting

Advanced Bladder Cancer

NCT07441889 2026-03-02

HER2 FPBMC in Patients With Metastatic Breast and Prostate Cancer (AM006)

23 enrolled

BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms

NCT01684397 2026-02-27

Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer

51 enrolled

Carcinoma, Renal Cell

NCT05639972 2026-02-27

E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers

GastrointestinalGenitourinaryGynecologicHead & Neck

15 enrolled

Anus Neoplasms, Uterine Cervical Neoplasms, Oropharyngeal Neoplasms, Penile Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms

NCT06085729 2026-02-27

Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)

Phase 1/2 Suspended

30 enrolled

Prostatic Neoplasms

NCT05672459 2026-02-25

A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors

31 enrolled

Kidney Neoplasms

NCT02522715 2026-02-24

Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer

37 enrolled 10 charts

Prostatic Neoplasms

NCT06457919 2026-02-19

A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer

50 enrolled

BreastEndocrineGastrointestinalGenitourinaryGynecologicNETSarcoma

Prostatic Neoplasms

NCT05000294 2026-02-18

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

Phase 1/2 Suspended

29 enrolled

Bile Duct Neoplasms, Breast Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vulvar Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT07410494 2026-02-18

SELECT-CAR-NK

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidOther hematologic neoplasmPlasma cellThoracic

85 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Carcinoma, Hepatocellular, Liver Neoplasms, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Multiple Myeloma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute

NCT07410676 2026-02-18

EBNK-ST-001

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicOther hematologic neoplasmSarcomaThoracic

83 enrolled

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Bronchogenic, Disease, Esophageal Neoplasms, Glioblastoma, Kidney Neoplasms, Leukemia, Liver Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms

NCT04506567 2026-02-17

Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC

Prostatic Neoplasms

NCT06236139 2026-02-17

Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer

48 enrolled

Prostatic Neoplasms

NCT06661902 2026-02-17

BURN

350 enrolled

Phase 1/2 Not yet recruiting

Prostatic Neoplasms

NCT07414940 2026-02-17

ACT-RESoLUTE

Prostatic Neoplasms

NCT01543659 2026-02-13

Clinical and Molecular Correlates of Positron Emission Tomography (PET) With 89Zr-DFO-huJ591 in Metastatic Prostate Cancer

77 enrolled

Phase 1/2 Not yet recruiting

Prostatic Neoplasms

NCT07407582 2026-02-12

Ph. I/II Sodium Thiosulfate for OtoProtection During Cisplatin (STOP-CIS)

25 enrolled

GenitourinaryHead & Neck

Head and Neck Neoplasms, Neoplasms, Testicular Neoplasms, Hearing Loss

NCT01517451 2026-02-11

Radiation and Androgen Ablation for Prostate Cancer

45 enrolled 11 charts

Adenocarcinoma of the Prostate

NCT04901702 2026-02-09

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

CNSGastrointestinalGenitourinarySarcoma

90 enrolled

Neoplasms, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

NCT04946370 2026-02-03

Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer

37 enrolled

Prostatic Neoplasms

NCT03474497 2026-01-29

UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade

DermatologicGenitourinaryHead & NeckThoracic

18 enrolled 13 charts

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT03543189 2026-01-29

Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy

44 enrolled

Prostatic Diseases, Prostatic Neoplasms

NCT03553602 2026-01-29

BEACON

Phase 1/2 Terminated

3 enrolled 7 charts

Prostatic Neoplasms

NCT04856189 2026-01-29

Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma

Phase 1/2 Terminated

4 enrolled 8 charts

Carcinoma, Transitional Cell

NCT04989946 2026-01-28

Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer

Prostatic Neoplasms

NCT05968144 2026-01-27

ADRIAN

30 enrolled

BreastGenitourinary

Frailty, Breast Neoplasms, Prostatic Neoplasms

NCT00625755 2026-01-23

A Phase I/II Study to Assess the Safety and Efficacy of Vaccinations With Allogeneic Dendritic Cells: Autologous Tumor-Derived Cells Subjected to Electrofusions in Patients With AJCC Stage IV Renal Cell Carcinoma

40 enrolled

Carcinoma, Renal Cell

NCT07363382 2026-01-23

The Value of GRPR PET Imaging for Diagnosis and Staging in Prostate Cancer

6 enrolled

Adenocarcinoma, Prostatic Neoplasms

NCT07363486 2026-01-23

Sequential Study of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer

9 enrolled

Prostatic Neoplasms

NCT07292168 2026-01-21

TAGNOT

BreastGenitourinaryHead & NeckThoracic

58 enrolled

Acrocephalosyndactylia, Breast Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Prostatic Neoplasms

NCT02473536 2026-01-16

Neo-adjuvant SABR for IVC Tumor Thrombus in Newly Diagnosed RCC

25 enrolled

Carcinoma, Renal Cell

NCT06085664 2026-01-15

A Pilot Presurgical Trial of REGN5678 (Anti-PSMA x CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical Prostatectomy

42 enrolled

Prostatic Neoplasms

NCT06835972 2026-01-15

A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)

43 enrolled

Carcinoma, Renal Cell

NCT05501054 2026-01-14

Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.

50 enrolled

Carcinoma, Renal Cell

NCT07219576 2026-01-13

PRISM

Phase 1/2 Enrolling by invitation

40 enrolled

GenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell

NCT05570994 2026-01-08

177Lu-HTK03170 in mCRPC With PSMA Positive Disease

50 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT02989584 2026-01-07

A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer

54 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06600698 2026-01-07

Safety and Efficacy of AGN-INM176 in Prostate Patients With Rising PSA

45 enrolled

Prostatic Neoplasms

NCT06970119 2026-01-07

A Multicenter, Open-label, Non-randomized Phase I/IIa Clinical Trial to Evaluate INR102 Injection in Patients With Prostate Cancer

55 enrolled